Radiation Oncology, Treatment Protocols
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
GI002 is permanently closed to accrual effective February 22, 2021. Sites need to continue to collect long-term follow-up data on enrolled patients.
As of February 12, 2018 Arm 2 is permanently closed having met its enrollment goal.
As of Tuesday, May 14th, 2019 at 9:00 am EST, NRG-GI002 (Arm 1 and 3) has met its accrual goal and is temporarily suspended.